Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

The Efficacy and Safety of Homoharringtonine Combined With Venetoclax and Azacitidine Versus Standard Chemotherapy or VA in the Treatment of Acute Myeloid Leukemia With High-risk, a Multicenter, Prospective, Randomized Study

NCT06810791 is registered in ClinicalTrials.gov with Nanfang Hospital, Southern Medical University as lead sponsor.

NCT NCT06810791
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT06810791 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
The Efficacy and Safety of Homoharringtonine Combined With Venetoclax and Azacitidine Versus Standard Chemotherapy or VA in the Treatment of Acute Myeloid Leukemia With High-risk, a Multicenter, Prospective, Randomized Study
Lead sponsor
Nanfang Hospital, Southern Medical University
Phase
Phase 3
Overall status
Recruiting
Start date
January 1, 2025
Completion date
December 31, 2026
Enrollment
876 (estimated)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

newly diagnosed acute myeloid leukemia with high risk